Nicotinamide as a radiosensitizer in tumours and normal tissues: The importance of drug dose and timing

Radiotherapy and Oncology

Volumn 45, Issue 2, 1997, Pages 167-174

  Horsman, Michael R ^a   Siemann, Dietmar W ^b   Chaplin, David J ^c   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF FLORIDA   (United States)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Early and late responding normal tissues; Murine tumours; Nicotinamide; Pharmacokinetics; Radiation

Indexed keywords

NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SARCOMA;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; INJECTIONS, INTRAPERITONEAL; LUNG; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; NIACINAMIDE; RADIATION-SENSITIZING AGENTS; SKIN; TREATMENT OUTCOME; URINARY BLADDER; X-RAYS;

EID: 0031281939     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)00127-8     Document Type: Article

References (44)

1. [1] Cartei, F., Danesi, R., Ducci, F., Fatigante, L., Caciagli, P.G., Del Tacca, M. and Laddaga, M. Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. Acta Oncol. 33: 969-973, 1994.
2. [2] Chaplin, D.J., Horsman, M.R. and Aoki, D.S. Nicotinamide, fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer 63: 109-113, 1991.
3. [3] Chaplin, D.J., Horsman, M.R. and Siemann, D.W. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate acutely and chronically hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time. Br. J. Cancer 68: 269-273, 1993.
4. [4] Chaplin, D.J., Horsman, M.R. and Trotter, M.J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour. J. Natl. Cancer Inst. 82: 672-676, 1990.
5. [5] Chouinard, G., Young, S.N., Annable, L. and Sourkes, T.L. Tryptophan-nicotinamide combination in depression. Lancet I: 249, 1977.
6. [6] De Vries, J.X., Gunthert, W. and Ding, R. Determination of nicotinamide in human plasma and urine by ion-pair reversed phase high-performance liquid chromatography. J. Chromatogr. 221: 161-165, 1980.
7. [7] Dragovic, J., Kim, S.H., Brown, S.L. and Kim, J.H. Nicotinamide pharmacokinetics in patients. Radiother. Oncol. 36: 225-228, 1995.
8. [8] Green, R.G. Subclinical pellagra: its diagnosis and treatment. Schizophrenia 2: 70-79, 1970.
9. [9] Haslam, R.H., Dalby, J.T. and Rademaker, A.W. Effects of mega-vitamin therapy on children with attention deficit disorders. Pediatrics 74: 103-111, 1984.
10. [10] Hawkins, D.R. Treatment of schizophrenia based on the medical model. J. Schizophrenia 2: 3-10, 1968.
11. [11] Hendry, J.H. Radionecrosis of normal tissue: studies on mouse tails. Int. J. Radiat. Biol. 33: 47-55, 1978.
12. [12] Hendry, J.H. Quantitation of the radiotherapeutic importance of naturally-hypoxic normal tissues from collated experiments with rodents using single doses. Int. J. Radiat. Oncol. Biol. Phys. 5: 971-976, 1979.
13. [13] Hendry, J.H., Moore, J.V., Hodgson, B.W. and Keene, J.P. The constant low oxygen concentration in all the target cells for mouse tail radionecrosis. Radiat. Res. 92: 172-181, 1982.
14. [14] Hendry, J.H. and Sutton, M.L. Care with radiosensitizers. Br. J. Radiol. 51: 927-928, 1978.
15. [15] Hirst, D.G., Brown, J.M. and Hazlehurst, J.L. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br. J. Cancer 46: 109-116, 1982.
16. [16] Hofer, A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia 1: 78-87, 1969.
17. [17] Horsman, M.R. Blood flow modification and oxygenation of experimental tumours. In: Bioreductive Drugs, Sensitizers, Oxygen and Radiotherapy, pp. 85-100. Editor: W. Dobrowsky. Facultas-Universitätsverlag, Vienna, 1993.
18. [18] Horsman, M.R. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol. 34: 571-587, 1995.
19. [19] Horsman, M.R., Chaplin, D.J. and Brown, J.M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat. Res. 109: 479-489, 1987.
20. [20] Horsman, M.R., Chaplin, D.J. and Overgaard, J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res. 50: 7430-7436, 1990.
21. [21] Horsman, M.R., Høyer, M., Honess, D.J., Dennis, I.F. and Overgaard, J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27: 131-139, 1993.
22. [22] Horsman, MR., Nordsmark, M., Khalil, A.A., Hill, S.A., Chaplin, D.J., Siemann, D.W. and Overgaard, J. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol. 33: 371-376, 1994.
23. [23] Horsman, M.R., Wood, P.J., Chaplin, D.J., Brown, J.M. and Overgaard, J. The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother. Oncol. 18: 49-57, 1990.
24. [24] Hoskin, P.J., Stratford, M.R.L., Saunders, M.I., Hall, D.W., Dennis, M.F. and Rojas, A. Administration of nicotinamide during CHART: pharmacokinetics, dose escalation, and clinical toxicity. Int. J. Radiat. Oncol. Biol. Phys. 32: 1111-1119, 1995.
25. [25] Jonsson, G.G., Kjellén, E., Pero, R.W. and Cameron, R. Radiosensitization effects of nicotinamide on malignant and normal mouse tissue. Cancer Res. 45: 3609-3614, 1985.
26. [26] Kaanders, J.H.A.M., Pop, L.A.M., Marres, H.A.M., van der Maazen, R.W.M., van der Kogel, A.J. and van Daal, W.A.J. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. Radiother. Oncol 37: 190-198, 1995.
27. [27] Kallman, R.F., Silini, G. and Van Putten, L.M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumours. J. Natl. Cancer Inst. 39: 539-549, 1967.
28. [28] Kjellén, E., Joiner, M.C., Collier, J.M., Johns, H. and Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments. Radiother. Oncol. 22: 81-91, 1991.
29. [29] Lee, I., Levitt, S.H. and Song, C.W. Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline. Int. J. Radiat. Biol. 64: 237-244, 1993.
30. [30] Lundbeck, F., Ulsø, N. and Overgaard, J. Cystometric evaluation of early and late irradiation damage to the mouse urinary bladder. Radiother. Oncol. 15: 383-392, 1989.
31. [31] Neumann, R., Rappold, E. and Pohl-Markl, H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br. J. Dermatol. 115: 77-80, 1986.
32. [32] Overgaard, J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int. J. Radiat. Oncol. Biol. Phys. 6: 1507-1517, 1980.
33. [33] Pickles, T., Graham, P., Syndikus, I., Rheaume, D.E.. Duncan, G.G., Green, A. and Marlow, C. Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother. Oncol. 40: 245-247, 1996.
34. [34] Pigott, K., Dische, S. and Saunders, M.I. Short communication: the addition of carbogen and nicotinamide to a palliative fractionation schedule for locally advanced breast cancer. Br. J. Radiol. 68: 215-218, 1995.
35. [35] Rojas, A., Hodgkiss, R.J., Stratford, M.R.L., Dennis, M.F. and Johns, H. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. Br. J. Cancer 68: 1115-1121, 1993.
36. [36] Rojas, A., Vojnovic, B., Johns, H., Joiner, M.C., Martindale, C., Fowler, J.F. and Denekamp, J. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules. Radiother. Oncol. 39: 53-64, 1996.
37. [37] Siemann, D.W., Horsman, M.R. and Chaplin, D.J. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother. Oncol. 31: 117-122, 1994.
38. [38] Stratford, M.R.L. and Dennis, M.F. Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. Cancer Chemother. Pharmacol. 34: 399-404, 1994.
39. [39] Stratford, M.R.L., Dennis, M.F., Hoskin, P.J., Saunders, M.I., Hodgkiss, R.J. and Rojas, A. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol. 35: 213-219, 1996.
40. [40] Vague, P., Vialettes, B., Lassmann-Vague, V. and Vallo, J.J. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet I: 619-620, 1987.
41. [41] van der Maazen, R.W.M., Thijssen, H.O.M., Kaanders, J.H.A.M., de Koster, A., Keyser, A., Prick, M.J.J., Grotenhuis, J.A., Wesseling, P. and van der Kogel, A.J. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother. Oncol. 35: 118-122, 1995.
42. [42] von der Maase, H., Overgaard, J. and Vaeth, M. Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother. Oncol. 5: 245-257, 1986.
43. [43] Zackheim, R.G. Topical 6-aminonicotinamide plus oral nicotinamide therapy for psoriasis. Arch. Dermatol. 114: 1632-1638, 1978.
44. [44] Zackrisson, B., Franzén, L., Henriksson, R., Littbrand, B., Stratford, M., Dennis, M., Rojas, A.M. and Denekamp, J. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol. 33: 377-381, 1994.